RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback